Vor Biopharma (VOR) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free VOR Stock Alerts $1.81 +0.01 (+0.56%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 1:39 PM | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential ExpansionMay 15 at 2:50 AM | americanbankingnews.comVor Biopharma (NYSE:VOR) Given Market Outperform Rating at JMP SecuritiesMay 15 at 2:50 AM | americanbankingnews.comVor Biopharma (NYSE:VOR) Stock Rating Reaffirmed by OppenheimerMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vor Biopharma’s Clinical and Financial FortitudeMay 14, 2024 | americanbankingnews.comWedbush Reiterates Outperform Rating for Vor Biopharma (NYSE:VOR)May 13, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Given "Market Outperform" Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $12.00 price objective on shares of Vor Biopharma in a report on Monday.May 13, 2024 | americanbankingnews.comHC Wainwright Research Analysts Decrease Earnings Estimates for Vor Biopharma Inc. (NYSE:VOR)May 11, 2024 | markets.businessinsider.comSilvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market PotentialMay 10, 2024 | markets.businessinsider.comPromising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor BiopharmaMay 10, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Receives Outperform Rating from WedbushWedbush restated an "outperform" rating and set a $11.00 price objective on shares of Vor Biopharma in a research report on Friday.May 9, 2024 | msn.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024May 9, 2024 | globenewswire.comVor Bio Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 6, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMay 3, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comVor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of DirectorsApril 23, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Earns "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and set a $11.00 price objective on shares of Vor Biopharma in a report on Tuesday.April 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialApril 1, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMarch 29, 2024 | finance.yahoo.comHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn SituationMarch 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessMarch 26, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)March 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)March 22, 2024 | marketbeat.comVor Biopharma's (VOR) Market Outperform Rating Reaffirmed at JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Friday.March 22, 2024 | marketbeat.comVor Biopharma Inc. Expected to Post Q1 2025 Earnings of ($0.24) Per Share (NYSE:VOR)Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities researchers at Wedbush issued their Q1 2025 earnings estimates for Vor Biopharma in a research report issued on Wednesday, March 20th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.24) for the quMarch 22, 2024 | finanznachrichten.deVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 21, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)March 21, 2024 | marketbeat.comVor Biopharma (NYSE:VOR) Price Target Cut to $12.00 by Analysts at Stifel NicolausStifel Nicolaus dropped their price target on Vor Biopharma from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday.March 21, 2024 | marketbeat.comOppenheimer Reaffirms "Outperform" Rating for Vor Biopharma (NYSE:VOR)Oppenheimer restated an "outperform" rating and set a $15.00 price target (down from $17.00) on shares of Vor Biopharma in a report on Thursday.March 20, 2024 | benzinga.comVor Biopharma: Q4 Earnings InsightsMarch 20, 2024 | finance.yahoo.comVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 20, 2024 | globenewswire.comVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateMarch 20, 2024 | marketbeat.comVor Biopharma (VOR) to Release Quarterly Earnings on ThursdayVor Biopharma (NYSE:VOR) will be releasing earnings on Thursday, March 21, Yahoo Finance reports.March 19, 2024 | msn.comIntellia Therapeutics doses first patient in pivotal in vivo CRISPR trialMarch 16, 2024 | finance.yahoo.comVOR Apr 2024 5.000 callMarch 5, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesFebruary 17, 2024 | finance.yahoo.comInstitutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the companyFebruary 15, 2024 | finance.yahoo.com2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)February 7, 2024 | finance.yahoo.comVor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finanznachrichten.dePersonnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are welcomed as new members of the Executive BoardJanuary 31, 2024 | msn.comVaxart spikes as B. Riley upgrades at long last after BARDA fundingJanuary 18, 2024 | marketbeat.comVor Biopharma's (VOR) "Outperform" Rating Reiterated at WedbushWedbush reiterated an "outperform" rating and set a $11.00 price objective on shares of Vor Biopharma in a research report on Thursday.January 18, 2024 | finanznachrichten.deVor Biopharma: Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate UpdateJanuary 17, 2024 | finance.yahoo.comVor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate UpdateJanuary 9, 2024 | markets.businessinsider.comBuy Rating Justified by CRISPR Therapeutics’ Strong Pipeline and Market PotentialDecember 14, 2023 | marketbeat.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by AnalystsShares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have been given a consensus rating of "Buy" by the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target amNovember 9, 2023 | finance.yahoo.comVor Bio Presents Positive Data Update on Trem-cel at HSCT² ConferenceNovember 8, 2023 | finanznachrichten.deVor Biopharma: Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company UpdateNovember 7, 2023 | msn.comVor Biopharma GAAP EPS of -$0.49 misses by $0.02November 7, 2023 | finance.yahoo.comVor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. VOR Media Mentions By Week VOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.100.49▲Average Medical News Sentiment VOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼121▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AUGX News Today ABEO News Today RZLT News Today IMUX News Today CLRB News Today LIFW News Today DBVT News Today BLUE News Today ADAG News Today FGEN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VOR) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
